









Markets
/
Stocks
/
nasdaq-gmab
/

Genmab A/S

GMAB

View Detailed Chart

21.780USD

+0.110+0.51%

Close 08/01, 16:00（ET）Quotes delayed by 15 min

1.38BMarket Cap

0.40P/E TTM



Genmab A/S

21.780

+0.110+0.51%

Overview Company Financials

Financials

Intraday

30m

Today

+0.51%

5 Days

-6.92%

1 Month

+7.29%

6 Months

+13.97%

Year to Date

+4.36%

1 Year

-22.88%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 12 analysts

BUY

Current Rating

31.000

Target Price

42.33%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

552

Total

Median

Average

Company name

Ratings

Analysts

Genmab A/S

GMAB

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Sell

Sell(6)

Neutral(3)

Buy(3)

Indicators

Sell(3)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.110

Neutral

RSI(14)

48.595

Neutral

STOCH(KDJ)(9,3,3)

22.197

Sell

ATR(14)

0.541

High Vlolatility

CCI(14)

-71.809

Neutral

Williams %R

75.434

Sell

TRIX(12,20)

0.283

Sell

StochRSI(14)

7.254

Oversold

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

22.282

Sell

MA10

22.480

Sell

MA20

21.989

Sell

MA50

21.647

Buy

MA100

20.734

Buy

MA200

21.130

Buy

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.

Ticker SymbolGMAB

CompanyGenmab A/S

CEODr. Jan G.J. Van De Winkel, Ph.D.

Websitehttps://www.genmab.com/